滨蒿内酯治疗非酒精性脂肪性肝病的作用及机制研究进展
摘要
<正>滨蒿内酯提取于菊科陈蒿,也来源于青蒿及石斛等,具有多种生物活性,在肝脏中主要作用为保肝利胆。非酒精性脂肪性肝病(NAFLD)是我国目前第一大肝脏疾病,以肝细胞脂肪变性、肝脏脂质积累为主要病理特征,发病机制尚不明确。近年来关于滨蒿内酯在NAFLD自然发展过程中的作用研究颇多,研究发现滨蒿内酯具有抑制肝细胞、脂肪组织炎症、抵抗类症因子介导的细胞毒性,及改善胰岛素抵抗、减轻氧化应激等作用。1 滨蒿内酯的来源滨蒿内酯是6,7-二甲氧基香
引文
[1]赵蕴馥,李沈昌.从沈阳产滨蒿中提取滨蒿内酯及收率考察[J].中国医科大学学报,1997(6):575-576.
[2]刘妍妍,虞泓,袁峰,等.滨蒿内酯和泽兰内酯在云南石斛物种中的分布[J].中国中药杂志,2013,38(21):3691-3695.
[3]郝双红,宗广辉,魏艳,等.滨蒿内酯的合成及其农用生物活性研究[J].青岛农业大学学报(自然科学版),2007,24(4):241-244.
[4]慕永平,刘平,王磊.茵陈蒿汤的发展及现代研究[J].中国实验方剂学杂志,2006,12(2):67-71.
[5]兰绍阳,余世锋,张达坤.茵陈蒿汤对肝内胆汁淤积湿热证大鼠肝组织NTCP表达的影响[J].中药新药与临床药理,2012,23(3):279-283.
[6]兰绍阳,佘世锋,陶双友.茵栀黄注射液改善TNF-α对大鼠原代肝细胞Mrp2表达的抑制研究[J].四川中医,2014,1(4):60-62.
[7]Yang DF,Yang J,Shi DS,et al.Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor[J].British J Pharmacol,2011.164(5):1547-1557.
[8]Fang H,Zhang A,Yu J,et al.Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome[J].Sci Rep,2016,6:37519.
[9]Younossi ZM,Koenig AB,Abdelatif D,et al:Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.
[10]Cichocki JA,Furuya S,Konganti K,et al Impact of nonalcoholic fatty liver disease on toxicokinetics of tetrachloroethylene in Mice[J].J Pharmacol Experiment Therapeut,2017,361(1):17-28.
[11]Musso G,Gambino R,Cassader M.Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease(NAFLD)[J].Progress Lip Res,2009,48(1):1-26.
[12]刘昱含,谢青.多重“打击”在非酒精性脂肪性肝病发病过程中的作用[J].肝脏,2016,21(3):219-221
[13]朱鹏.香豆素类化合物抗非酒精性脂肪肝活性体外筛选[D].湖北大学,2017.
[14]徐娇雅.降脂颗粒及其成分滨蒿内酯对NASH脂毒性肝损伤的作用及机制研究[D].上海中医药大学,2016.
[15]马春霞,朱瑞,李晓娟,等.危重症应激性高血糖患者内毒素、NO与胰岛素组分关系的研究[J].宁夏医学杂志,2017,39(1):22-24.
[16]Cipolletta D,Fenerer M,Li A,et al.PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells[J].Nature,2012,486(7404):549-553.
[17]Noh JR,Kim YH,Huang JH,et al.Scoparone inhibits adipocyte differentiation through down-regulation of peroxisome proliferators-activated receptorγin 3T3-L1 preadipocytes[J].Food Chem,2013,141(2):723-730.
[18]Jang SI,Kim YJ,Lee WY,et al.Scoparone from Artemisia capillaris inhibits the release of inflammatory mediators in RAW 264.7 cells upon stimulation cells by interferon-gamma Plus LPS[J].Arch Pharm Res,2005,28(2):203-208.
[19]Jang SI,Kim YJ,Kim HJ,et al.Scoparone inhibits PMA-induced IL-8 and MCP-1 production through suppression of NF-kappaB activation in U937 cells[J].Life Sci,2006,78(25):2937-2943.
[20]李杰,安永,于建国.肝纤维化与肝硬化防治研究进展[J].中华消化病与影像杂志(电子版),2012,2(5):38-42.
[21]Liu X,Zhao X.Scoparone attenuates hepatic stellate cell activation through inhibiting TGF-beta/Smad signaling pathway[J].Biomed Pharmacother,2017,93:57-61.
[22]何婷晔.滨蒿内酯通过CAR对CYP450代谢酶和MDRI影响的体外研究[D].中南大学,2007.
[2]刘妍妍,虞泓,袁峰,等.滨蒿内酯和泽兰内酯在云南石斛物种中的分布[J].中国中药杂志,2013,38(21):3691-3695.
[3]郝双红,宗广辉,魏艳,等.滨蒿内酯的合成及其农用生物活性研究[J].青岛农业大学学报(自然科学版),2007,24(4):241-244.
[4]慕永平,刘平,王磊.茵陈蒿汤的发展及现代研究[J].中国实验方剂学杂志,2006,12(2):67-71.
[5]兰绍阳,余世锋,张达坤.茵陈蒿汤对肝内胆汁淤积湿热证大鼠肝组织NTCP表达的影响[J].中药新药与临床药理,2012,23(3):279-283.
[6]兰绍阳,佘世锋,陶双友.茵栀黄注射液改善TNF-α对大鼠原代肝细胞Mrp2表达的抑制研究[J].四川中医,2014,1(4):60-62.
[7]Yang DF,Yang J,Shi DS,et al.Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor[J].British J Pharmacol,2011.164(5):1547-1557.
[8]Fang H,Zhang A,Yu J,et al.Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome[J].Sci Rep,2016,6:37519.
[9]Younossi ZM,Koenig AB,Abdelatif D,et al:Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.
[10]Cichocki JA,Furuya S,Konganti K,et al Impact of nonalcoholic fatty liver disease on toxicokinetics of tetrachloroethylene in Mice[J].J Pharmacol Experiment Therapeut,2017,361(1):17-28.
[11]Musso G,Gambino R,Cassader M.Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease(NAFLD)[J].Progress Lip Res,2009,48(1):1-26.
[12]刘昱含,谢青.多重“打击”在非酒精性脂肪性肝病发病过程中的作用[J].肝脏,2016,21(3):219-221
[13]朱鹏.香豆素类化合物抗非酒精性脂肪肝活性体外筛选[D].湖北大学,2017.
[14]徐娇雅.降脂颗粒及其成分滨蒿内酯对NASH脂毒性肝损伤的作用及机制研究[D].上海中医药大学,2016.
[15]马春霞,朱瑞,李晓娟,等.危重症应激性高血糖患者内毒素、NO与胰岛素组分关系的研究[J].宁夏医学杂志,2017,39(1):22-24.
[16]Cipolletta D,Fenerer M,Li A,et al.PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells[J].Nature,2012,486(7404):549-553.
[17]Noh JR,Kim YH,Huang JH,et al.Scoparone inhibits adipocyte differentiation through down-regulation of peroxisome proliferators-activated receptorγin 3T3-L1 preadipocytes[J].Food Chem,2013,141(2):723-730.
[18]Jang SI,Kim YJ,Lee WY,et al.Scoparone from Artemisia capillaris inhibits the release of inflammatory mediators in RAW 264.7 cells upon stimulation cells by interferon-gamma Plus LPS[J].Arch Pharm Res,2005,28(2):203-208.
[19]Jang SI,Kim YJ,Kim HJ,et al.Scoparone inhibits PMA-induced IL-8 and MCP-1 production through suppression of NF-kappaB activation in U937 cells[J].Life Sci,2006,78(25):2937-2943.
[20]李杰,安永,于建国.肝纤维化与肝硬化防治研究进展[J].中华消化病与影像杂志(电子版),2012,2(5):38-42.
[21]Liu X,Zhao X.Scoparone attenuates hepatic stellate cell activation through inhibiting TGF-beta/Smad signaling pathway[J].Biomed Pharmacother,2017,93:57-61.
[22]何婷晔.滨蒿内酯通过CAR对CYP450代谢酶和MDRI影响的体外研究[D].中南大学,2007.